Investigating New Trial Design Approaches, Efficient Application of Biomarkers Patient Recruitment Strategies to Drive Oncology Clinical Development and Speed Time to Market

Oncology is undoubtedly the largest investment area for the pharmaceutical industry with latest estimates putting the market at a huge $55 billion. However, there is disparity between this investment in oncology development and the rate of drug approval and there is a drive to bridge this gap through better decision making and optimising clinical development.

Our industry-wide survey has highlighted that the biggest obstacles, yet potential time-savers include;

• Trial design
• Implementing biomarkers and functional imaging
• Patient recruitment and retention strategies
• Effective use of preclinical data

Do you know what strategies your competitors are implementing over the next 12 months?

Unlocking the potential of alternative trial designs has the power to greatly reduce the time and cost of your trial and speed time to market. With no less than 8 expert-led sessions providing insight into alternative approaches to trial design Pharma IQ's 2nd Annual Optimising Clinical Development in Oncology conference can't be missed!

The event takes place on 15-16 March 2011 in London and is one half of Europe's leading Clinical Trials Summit.

JW McBlane, Clinical Assessor, MHRA will also be giving exclusive insight into the agency's views of the new ICH S9 guidelines. This update will allow you to begin trials on the basis of reduced preclinical data sets and understand what the UK agency deems acceptable, allowing you to minimise your trial time and ensure first time regulatory approval.

Download the brochure here for more details and the full speaker line up.

Sponsor	Media Partners